Your browser doesn't support javascript.
Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease
Acta Pharmaceutica Sinica B ; (6): 511-531, 2022.
Article in English | WPRIM | ID: wpr-929312
Responsible library: WPRO
Aging is by far the most prominent risk factor for Alzheimer's disease (AD), and both aging and AD are associated with apparent metabolic alterations. As developing effective therapeutic interventions to treat AD is clearly in urgent need, the impact of modulating whole-body and intracellular metabolism in preclinical models and in human patients, on disease pathogenesis, have been explored. There is also an increasing awareness of differential risk and potential targeting strategies related to biological sex, microbiome, and circadian regulation. As a major part of intracellular metabolism, mitochondrial bioenergetics, mitochondrial quality-control mechanisms, and mitochondria-linked inflammatory responses have been considered for AD therapeutic interventions. This review summarizes and highlights these efforts.

ACE2, angiotensin I converting enzyme (peptidyl-dipeptidase A) 2; AD, Alzheimer's disease; ADP, adenosine diphosphate; ADRD, AD-related dementias; Aβ, amyloid β; CSF, cerebrospinal fluid; Circadian regulation; DAMPs; DAMPs, damage-associated molecular patterns; Diabetes; ER, estrogen receptor; ETC, electron transport chain; FCCP, trifluoromethoxy carbonylcyanide phenylhydrazone; FPR-1, formyl peptide receptor 1; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; HBP, hexoamine biosynthesis pathway; HTRA, high temperature requirement A; Hexokinase biosynthesis pathway; I3A, indole-3-carboxaldehyde; IRF-3, interferon regulatory factor 3; LC3, microtubule associated protein light chain 3; LPS, lipopolysaccharide; LRR, leucine-rich repeat; MAVS, mitochondrial anti-viral signaling; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; Mdivi-1, mitochondrial division inhibitor 1; Microbiome; Mitochondrial DNA; Mitochondrial electron transport chain; Mitochondrial quality control; NLRP3, leucine-rich repeat (LRR)-containing protein (NLR)-like receptor family pyrin domain containing 3; NOD, nucleotide-binding oligomerization domain; NeuN, neuronal nuclear protein; PET, fluorodeoxyglucose (FDG)-positron emission tomography; PKA, protein kinase A; POLβ, the base-excision repair enzyme DNA polymerase β; ROS, reactive oxygen species; Reactive species; SAMP8, senescence-accelerated mice; SCFAs, short-chain fatty acids; SIRT3, NAD-dependent deacetylase sirtuin-3; STING, stimulator of interferon genes; STZ, streptozotocin; SkQ1, plastoquinonyldecyltriphenylphosphonium; T2D, type 2 diabetes; TCA, Tricarboxylic acid; TLR9, toll-like receptor 9; TMAO, trimethylamine N-oxide; TP, tricyclic pyrone; TRF, time-restricted feeding; cAMP, cyclic adenosine monophosphate; cGAS, cyclic GMP/AMP synthase; hAPP, human amyloid precursor protein; hPREP, human presequence protease; i.p., intraperitoneal; mTOR, mechanistic target of rapamycin; mtDNA, mitochondrial DNA; αkG, alpha-ketoglutarate
Full text: Available Index: WPRIM (Western Pacific) Language: English Journal: Acta Pharmaceutica Sinica B Year: 2022 Type: Article





Full text: Available Index: WPRIM (Western Pacific) Language: English Journal: Acta Pharmaceutica Sinica B Year: 2022 Type: Article